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Cardiovascular disease is one of the most frequent causes of mortality 
and morbidity worldwide. Several variables have been identified as 
risk factors for cardiovascular disease. Recently, the role of receptor 
activator of nuclear factor kappa B, receptor activator of nuclear factor 
kappa B ligand, and the osteoprotegerin system has been recognized as 
more important in the pathogenesis of cardiovascular disease. Besides 
their roles in the regulation of bone resorption, these molecules 
have been reported to be associated with the pathophysiology of 
cardiovascular disease. There are conflicting data regarding the 
impact of osteoprotegerin, a glycoprotein with a regulatory role in the 
cardiovascular system. The aim of this review is to discuss the current 
knowledge and the role of osteoprotegerin in cardiovascular disease.
Keywords: Cardiovascular disease, heart, inflammatory markers, 
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Cardiovascular disease (CVD) is one of the most frequent causes 
of mortality and morbidity among both men and women worldwide 
(1). Several studies conducted on CVD pathogenesis have identified 
several variables as risk factors (2-5). The complex pathophysiology 
of CVD is still a point of interest. In recent years, the role of 
receptor activator of nuclear factor kappa B (RANK), RANK 
ligand (RANK-L), and the osteoprotegerin (OPG) system has been 
receiving more research attention in terms of the pathogenesis of 
CVD. OPG was first described by Simonet et al. (6) as a regulator 
protein for bone metabolism and vascular calcification, which is 
produced by several tissues, including smooth muscle cells and 
the endothelium of the human vasculature (7-10). In addition 
to their roles in the regulation of bone resorption in calcium and 
immunologic reactions, RANK, RANK-L, and the OPG system 
have also been found to be associated with CVD pathophysiology 
(7-9). Several trials have reported higher OPG plasma levels in 
patients with coronary artery disease (CAD), peripheral artery 
disease (PAD), chronic heart failure (CHF), and atrial fibrillation, 
suggesting the association between OPG and CVD (11-16).
OSTEOPROTEGERIN: STRUCTURE, FUNCTION, AND 
METABOLISM
OPG is a soluble glycoprotein that is synthesized from 401 amino 
acid residues arranged into 7 structural domains (Figure 1). After 
losing 21 amino acids, it converts into a mature soluble glycoprotein 
with 380 amino acids. It is found in the extracellular fluid in the form 
of either a 60-kDa monomer or a 120-kDa dimer, linked by disulfide 
bonds. OPG is a member of the tumor necrosis factor (TNF) receptor 
superfamily and serves as a decoy receptor for RANK-L and TNF-
related apoptosis-inducing ligand (TRAIL). OPG is also a key 
protein for bone metabolism. By binding to RANK-L, OPG inhibits 
the interaction between RANK and RANK-L, which prevents the 
osteoclastic differentiation of stromal cells. On the other hand, by 
binding to TRAIL, it inhibits the apoptosis of transformed cells and 
tumor cells (6-9).
Of the 7 structural domains of OPG, domains 1-4 contain cysteine-
rich N-terminal amino acids. These domains bind to RANK-L and 
inhibit osteoclast formation from osteoclast precursors. Domains 
5-6 bind to TRAIL and inhibit TRAIL-induced apoptosis. Domain 
7 contains the C-terminal amino acid, which is the heparin-binding 
region of OPG (10,17,18). Although OPG is primarily produced 
by bone marrow stromal cells, it can also be expressed in dendritic 
cells and B lymphocytes (19). 1-α 25 hydroxycholecalciferol, 
interleukin-1 (IL-1), TNF-α, IL-6, IL-7, IL-11, IL-18, calcium and 
estrogen, transforming growth factor beta, bone morphogenetic 
protein-2, fibroblast growth factor, angiotensin 2, and platelet-
derived growth factor are known to upregulate the expression 
of OPG, whereas immunosuppressants, parathyroid hormone, 
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glucocorticoids, insulin-like growth factor-1, prostaglandin E2, 
and peroxisome proliferator-activated receptor gamma ligands 
downregulate OPG production (20-23). The tensile force applied 
on osteoblasts is a mechanical stimulus that also increases OPG 
synthesis. Moreover, several studies have demonstrated that 
aerobic exercise is associated with increased OPG levels (24).
Serum OPG levels are associated with its renal clearance. OPG 
levels increase with the reduction of renal creatinine clearance 
(25). Further increases can be seen in patients with end-stage 
renal disease receiving hemodialysis, as OPG monomer cannot be 
removed through the polysulfone membrane during hemodialysis 
(25). In addition, OPG level increases with advanced age, 
especially in the presence of diabetes mellitus (DM) (14,26-31). 
Most of the epidemiologic studies have demonstrated a positive 
correlation between age and OPG levels (30,31). OPG levels were 
found to be increased with age in both men and women (30). 
Premenopausal women had higher OPG levels than men below 
age 50 years, whereas postmenopausal women had similar OPG 
serum levels compared with an age-matched male population 
(30). Moreover, in the Dallas Heart Study, women had higher 
OPG levels than men, which were compatible with the majority 
of other epidemiologic studies (32,33). Based on these results, 
investigators also concluded that gender difference in OPG levels 
suggests that sex steroids regulate OPG expression in vivo (34). 
Estrogen enhancement of OPG secretion by osteoblastic cells 
may play a major role in the antiresorptive action of estrogen 
on bone (35). Khosla et al. (30) demonstrated that OPG levels 
were positively correlated with bone turnover markers in the 
male gender. In another study, parenteral administration of OPG 
prevented bone resorption in postmenopausal women (36). These 
studies suggest that OPG levels increase concomitantly with bone 
turnover markers as a compensatory response to enhanced bone 
resorption process. Moreover, there are several studies indicating 
that OPG deficiency is primarily associated with osteoporosis 
and arterial calcification (13,37). In addition, osteoporosis was 
reported to be accompanied by severe vascular calcification in 
OPG-deficient mice (7).
Relationship Between Osteoprotegerin Levels and 
Cardiovascular Disease
Coronary artery calcification (CAC) is a well-known indicator 
for atherosclerotic plaque burden. The factors that interfere with 
CAC also interfere with coronary atherosclerosis and CVD, 
respectively (38). According to clinical studies, vascular calcium 
burden is an indicative marker for the severity of atherosclerosis 
and arteriolosclerosis (39). Several studies have shown that the 
RANK–RANK-L–OPG system is related to atherosclerotic plaque 
calcification (40,41).
Relationship between osteoprotegerin levels and stable coronary 
artery disease: Several studies have shown that OPG levels are 
predictive of CAD (11,12,42,43). Lieb et al. (11) measured OPG 
levels in 3.250 Framingham Heart Study participants and found 
a positive association between circulating OPG levels (but not 
RANK-L) and CVD incidence and mortality. Some investigators 
have demonstrated a positive correlation between circulating 
OPG levels and the severity of atherosclerosis and the number of 
diseased vessels, especially in patients with type 2 DM (12,26,42). 
Ghaffari et al. (43) reported a significant relationship between 
serum OPG levels and coronary artery stenosis. Furthermore, they 
found that major adverse cardiovascular events occurred more 
often in patients with higher baseline OPG levels. Kiechl et al. 
(44) concluded that OPG was an independent risk factor for the 
onset of CVD and progression of atherosclerosis. In addition, they 
found that OPG was independently and significantly related to 
incident CVD and vascular mortality (44). Poornima et al. (45) 
showed that in postmenopausal women, the higher OPG levels 
were associated with higher CAC. In a study comparing OPG 
levels between patients with cardiac syndrome X (CSX), healthy 
obese subjects, and healthy lean subjects, it was found that OPG 
levels were significantly lower in patients with CSX than those 
in healthy lean subjects. The authors concluded that low OPG 
levels might play a role in systemic microvascular abnormalities 
observed in patients with CSX (46). OPG levels were found to be 
indicative of cardiovascular morbidity and mortality in patients 
with chronic kidney disease (47-49).
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FIG. 1. Schematic drawing of the osteoprotogerin molecule.
TABLE 1. Comparison of serum osteoprotegerin levels in different patient 
populations 
OPG
Healthy subjects ↔
Stable CAD ↑
ACS ↑↑
STEMI ↑↑
NSTEMI ↑↑
PAD ↔↑ 
Stroke ↔↑
CHF ↑
Valvular heart disease ↓
Hypertension ↔↑
DM ↔↑
DM with end-organ damage ↑
Obesity ↔↑↓
Metabolic syndrome ↔↑↓
Hyperlipidemia ↔↑
ACS: acute coronary syndrome; CAD: coronary artery disease; CHF: chronic heart 
failure; DM: diabetes mellitus; NSTEMI: myocardial infarction without ST elevation; 
OPG: osteoprotegerin; PAD: peripheral artery disease; STEMI: myocardial infarction 
with ST elevation; ↔:  normal level; ↑: increased level; ↑↑: more increased level;  
↔↑: normal level or increased level; ↓: decreased level; ↔↑↓: conflict results
Relationship between osteoprotegerin levels and Acute 
Coronary syndrome: In patients with ST-elevation myocardial 
infarction (STEMI) who underwent primary percutaneous coronary 
intervention, the OPG levels were found to be significantly 
associated with worse long-term cardiac outcomes (50). Jansson et 
al. (51) showed that OPG was an independent predictor for long-
term mortality and CHF in patients with unstable angina pectoris 
(USAP). Moreover, Luo et al. (52) investigated OPG and OPG/
RANK-L levels in patients with stable angina pectoris (SAP) and 
Acute Coronary syndrome (ACS). They found that serum OPG 
and OPG/RANK-L levels were significantly higher in the ACS 
group than in the SAP group. In the control group, which consisted 
of healhy subjects, the OPG and OPG/RANK-L levels were 
significantly lower than those of both the ACS and the SAP groups 
(52). However, in another study involving patients with SAP, 
USAP, and non-STEMI, the OPG levels showed no correlation with 
the severity of CAD, which might be due to OPG and/or RANK-L 
polymorphism and some other possible genetic variations, but it may 
be accepted as an indicator of coronary atherosclerosis (53). Higher 
OPG levels detected in patients with ACS might be associated with 
increased cytokine levels. This increase may be a proatherogenic 
pathway for further inflammation. Zauli et al. (54) showed that 
endogenously released OPG in response to TNF-α promoted 
an increased expression of adhesion molecules and leukocyte–
endothelial cell interaction, which aggravates inflammation.
Relationship Between Osteoprotegerin Levels and Peripheral 
Artery Disease
Multiple studies that had been carried out in various patient 
groups to evaluate the association between OPG and PAD found 
significant correlations (55-57). OPG levels appear to predict 
PAD in several patient groups. Lee et al. (56) demonstrated a 
positive correlation between OPG levels and cardio-ankle vascular 
index, which predicts atherosclerosis in hypertensive patients, 
thus suggesting arterial stiffness. In a study performed in patients 
with type 2 DM, serum OPG levels were higher in those with 
PAD than in those without PAD (57). In another study involving 
patients with nonalcoholic fatty liver disease (NAFLD), the OPG 
level was found to be higher in patients who had lower aortic flow 
propagation velocity and higher epicardial fat thickness (58).
Relationship Between Osteoprotegerin Levels and Stroke
Several studies have demonstrated higher OPG levels in patients 
with atherosclerotic cerebrovascular disease than those in healthy 
subjects (44,59,60). Carotid intima-media thickness (CIMT) is 
one of the risk factors predicting stroke and CVD (61,62). Kiechl 
et al. (44) also showed that OPG levels were associated with the 
severity and progression of carotid artery disease. Patients with 
chronic kidney disease and patients with increased OPG levels 
had significantly higher CIMT values than those in subjects with 
lower OPG levels (47). In women with gestational DM, increased 
serum OPG levels showed a positive correlation with CIMT (59). 
There are conflicting data regarding the association between stroke 
severity and OPG levels. In one study, no association was found 
between the risk of ischemic stroke and OPG levels (63). However, 
another study reported that plasma OPG levels were higher in 
patients with severe stroke (64). Mogelvang et al. (60) evaluated 
the association between plasma OPG and high sensitive C-reactive 
protein (CRP) levels and hospitalization for ischemic stroke, 
ischemic heart disease (IHD), and all-cause mortality. They found 
that OPG levels were an independent predictor of combined end-
points of ischemic stroke, IHD, and all-cause mortality. Along with 
the predictive value of OPG in ischemic stroke, Guldiken et al. (65) 
demonstrated that OPG was also associated with stroke subtypes.
Relationship Between Osteoprotegerin Levels and Chronic 
Heart Failure
OPG is a secretory glycoprotein that may exert a compensatory 
response to increased inflammatory activity in patients with 
CHF. Omland et al. (66) assessed the relationship between OPG 
levels and left ventricular (LV) function in patients who were 
enrolled in the Dallas Heart study. High levels of OPG were 
found to be associated with increased LV end-systolic volume 
and decreased LV ejection fraction (66). After adjusting for 
potential confounders in sex-specific multivariable models, 
OPG levels were found to be positively correlated with LV 
thickness, mass, and LV concentricity index in men, but 
not in women (66). In another study, serum OPG levels 
were predictive of CHF development in patients with ACS, 
independent of conventional risk markers such as troponin I, 
CRP, B-type natriuretic peptide, and ejection fraction (67). 
Moreover, CHF was shown to be associated with increased 
OPG–RANK–RANK-L axis, indicating inflammation 
characterized by matrix degradation and remodeling of the 
myocardial tissue (16).
Relationship Between Osteoprotegerin Levels and Valvular 
Heart Disease
Valvular heart disease is associated with inflammation and 
calcification of valve tissue. Proinflammatory cytokines activate the 
endothelial cells and increase OPG release (68). It was shown that 
increased OPG levels were associated with decreased osteoclastic 
differentiation in stenosis of aortic valves (69). Moreover, 
calcification of aortic valves in the elderly has been attributed 
to the inflammatory milieu, which promotes the osteogenic 
transformation of valvular cells (69,70). LDLr ˉ/ˉ mice expressing 
only apolipoprotein B100 were prone to develop aortic valve 
calcification. Weiss et al. (71) investigated the impact of exogenous 
OPG on aortic valve calcification in hypercholesterolemic LDLr 
ˉ/ˉ Apob100/100 mice and found that exogen OPG attenuates 
osteogenic transformation of valve cells and bone-like matrix 
synthesis, indicating that the aortic valve function was protected 
by the OPG treatment (71).
Relationship Between Osteoprotegerin Levels and 
Hypertension
The renin–angiotensin–aldosterone system is one of the hallmarks 
in blood pressure regulation. Some studies have demonstrated the 
indirect effects of angiotensin II on the activation of osteoclasts via the 
activation of RANK-L gene expression in osteoblasts (72,73). Based 
on these data, it can be speculated that blood pressure and OPG may 
have an interactive relationship. It has been shown that angiotensin II 
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blockage downregulates OPG levels in vitro, suggesting the possible 
link between high OPG levels and increased blood pressure (74). It 
may be suggested that increased OPG levels might be a protective 
response to vascular stiffness observed in hypertensive subjects. Wang 
et al. (75) showed that patients with higher carotid–femoral pulse 
wave velocity measurement, which is a gold standard for assessing 
arterial stiffness (76), had higher OPG levels. In the Dallas Heart 
study, higher OPG levels were also associated with hypertension (32). 
Browner et al. (14) showed that OPG levels were slightly higher in 
women with high blood pressure than in those with normal blood 
pressure, especially in patients aged ≥65 years (14). These results may 
be attributed to the relationship between OPG levels, arterial stiffness, 
and inflammation. Hypertension and arterial stiffness associated 
with vascular calcification and decreased elasticity may increase 
inflammation and expression on OPG in order to decrease the vascular 
stiffness (33). In several studies, the association between OPG levels 
and blood pressure was assessed along with other cardiovascular risk 
factors. Akyuz et al. (77) compared the OPG levels of resistant and 
nonresistant hypertension in patients with Obstructive Sleep Apnea 
syndrome. They also assessed the relationship between CIMT, apnea–
hypopnea index (AHI), and OPG levels among the study groups. 
They found that OPG levels were higher in patients with resistant 
hypertension than in patients with nonresistant hypertension (77). 
Moreover, they found no relationship between AHI and OPG levels 
but showed a positive correlation between CIMT and OPG levels in 
resistant hypertensive patients. However, this finding did not suggest 
a direct cause-and-effect relationship between higher OPG levels and 
high blood pressure (77). In contrast to these findings, no significant 
relationships were found between blood pressure and OPG levels in 
a Korean women study that was performed in premenopausal and 
postmenopausal women (78). The difference in the results between 
these two studies might be due to the different characteristics of the 
study participants and the different assays used to measure OPG levels 
(77,78).
Relationship Between Osteoprotegerin Levels and Diabetes 
Mellitus
Numerous studies have shown that serum OPG levels were 
higher in patients with DM than in those without DM (28,14,79). 
Different investigators have reported that serum OPG levels were 
increased in patients with type 1 and type 2 DM (28,80,81). OPG 
levels were also found to be higher in patients with longer duration 
of DM. Furthermore, in patients with DM and CVD, serum OPG 
levels were found to be higher than those in patients with DM 
and without CVD (81,82). OPG levels were shown to predict 
subclinical atherosclerosis and near-term cardiovascular events in 
uncomplicated type 2 DM (42). Diabetic end-organ damage was 
more likely to be observed in patients with higher OPG levels 
(28). In a study designed to determine whether OPG could be a 
marker for nephropathy in type 1 DM, OPG levels were found 
to be high only in patients with nephropathy; however, there 
was no significant relationship between other microvascular and 
macrovascular complications and OPG levels (83). Experimental 
studies have shown that increased OPG levels in patients with DM 
were related to proinflammatory cytokines such as TNF-α and IL-6 
rather than high serum glucose levels (84). These data indicate 
that the increased OPG levels in patients with DM are related to 
proinflammatory cytokines but are not related to insulin and high 
glucose levels (79,84,85).
Relationship Between Osteoprotegerin Levels and Obesity
There is still a conflict of data regarding the relationship between 
obesity and serum OPG levels, which might be attributed to 
the difference between the sample groups and methods, such as 
comorbidities and demographic features of patients of each study 
and the assays used for measuring OPG levels. Gannage-Yared et 
al. (86) found no correlation between body mass index and OPG 
levels, but they showed a positive correlation between insulin 
sensitivity and CRP levels and OPG levels in obese patients, 
suggesting that the inflammatory process in obesity promotes 
OPG increase. Ashley et al. (24) designed a study to examine the 
relationship between OPG levels, obesity, and insulin sensitivity 
in a healthy population. OPG levels were found to be significantly 
lower in obese subjects than in normal-weight and overweight 
subjects. In addition, a positive relationship was found between 
OPG levels and insulin sensitivity among all subjects (24). 
Consistent with these findings, a study involving obese, healthy, 
and lean subjects found that OPG levels were significantly lower 
in the obese group than in the lean controls (87). Furthermore, 
lower OPG levels were found in obese subjects with elevated 
insulin resistance than those found in lean subjects and in obese 
subjects with low insulin resistance (87). The relation between 
circulating OPG and insulin resistance assessed HOMA-IR was in 
investigated at obese and normal-weight women in premenopausal 
period (88). OPG showed a negative correlation with insulin and 
HOMA-IR in premenopausal obese women (88). According to 
these results, it may be suggested that increased insulin levels 
are associated with decreased OPG levels. The mechanism of 
decreased OPG levels in insulin-resistant obese subjects remains 
unclear. Several studies have shown that lower OPG levels 
observed in obese subjects are attributed to the possible inhibitory 
effect of insulin on OPG expression (89,90). In an experimental 
study designed with 9 healthy male subjects, it was shown that 
acute hyperglycemia did not increase OPG levels in nondiabetic 
subjects, whereas hyperinsulinemia inhibited OPG expression 
(89). This finding might be attributed to a possible inhibitory 
effect of insulin on OPG expression and explain the decreased 
OPG levels in healthy obese subjects.
Relationship Between Osteoprotegerin Levels and Metabolic 
Syndrome
Considering that the Metabolic syndrome (MetS) is a state of 
obesity, insulin resistance, and inflammation, increased white 
adipose tissue (WAT) in obese subjects has become a much 
important issue (91,92). WAT acts as an endocrine organ that 
promotes inflammation due to its macrophage-rich content (93,94). 
As inflammation promotes OPG expression, it can be suggested 
that OPG levels are accepted to be higher in patients with MetS. On 
the other hand, there are conflicting data regarding the relationship 
between OPG levels and MetS. According to animal studies, OPG 
levels were found to be increased in mice fed with a high-fat diet 
(95). Bernardi et al. (95) reported higher OPG levels in newly 
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diagnosed MetS group than in healthy subjects after adjusting 
for other risk factors, which might be due to the inflammatory 
milieu in MetS causing increased OPG expression. However, some 
investigators suggest that there is no correlation between MetS and 
serum OPG levels (86). The different results may be attributed to 
the different study groups differing in terms of variables such as 
sex, age, comorbidities, and diagnostic criteria of MetS.
Relationship Between Osteoprotegerin Levels and 
Hyperlipidemia
The relationship between lipid profile and OPG levels is still 
a matter of debate. Lipid profile has been the subject of few 
studies, and controversial reports have been published (15, 
26,96). The different results obtained are attributed to different 
study populations. In Korean healthy female subjects, higher 
total cholesterol and low-density lipoprotein (LDL) levels were 
associated with higher OPG levels (78). In the Dallas Heart 
study (32), the participants’ higher OPG levels were found to 
be associated with hypercholesterolemia. In contrast, Gannage-
Yared et al. (86) found no correlation between OPG levels and 
lipid profile in obese subjects. These studies suggest that the 
increased OPG expression is a protective response to elevated 
LDL levels that promote the atherosclerotic process. Moreover, it 
can be speculated that higher OPG levels in hypercholesterolemia 
are a result of the inflammatory milieu caused by increased LDL 
and total cholesterol levels. LDL-lowering therapy was shown 
to have conflicting results in patients with type 2 DM. Although 
simvastatin treatment reduced OPG levels (96), lovastatin and 
pravastatin treatment increased the plasma levels of OPG (97,98).
ROLE OF OSTEOPROTEGERIN AS A 
CARDIOPROTECTIVE VERSUS REACTIVE 
INFLAMMATORY MARKER: THE CHICKEN OR THE 
EGG PARADOX
Recent studies have demonstrated that serum OPG levels are 
a strong predictor of cardiovascular mortality and morbidity 
(11,12). In a systematic review performed by Hosbond et al. 
(99), the authors evaluated the relationship between OPG and 
CAD, ACS, PAD, and cerebrovascular disease. They analyzed 14 
studies with clearly defined cohorts and found that OPG levels are 
associated with the presence and severity of stable CAD, ACS, 
and cerebrovascular disease, but not associated with PAD. The 
atherosclerotic process involves mechanical and immunological 
mechanisms, and arterial calcification is an important indicator 
of atherosclerotic plaque burden. According to recent studies, in 
contrast to our previous knowledge, vascular calcification is an 
actively regulated process and human vascular smooth muscle 
cells can express osteoblastic transcription factors (100,101) and 
bone-regulating proteins such as matrix Gla protein, osteopontin, 
osteocalcin, collagen 1, osteonectin, bone morphogenic proteins, 
alkaline phosphatase, and bone sialoprotein. The calcification 
can occur either in an intimal or in a medial layer of arteries. 
Remodeling of the arterial wall includes degeneration of elastin 
fibers, increase in collagen fibers, and thickening of the arterial 
wall (102,103). As a result, calcification of elastic components of 
the medial layer increases the arterial wall thickness, thus causing 
arterial stiffness. Increased arterial stiffness causes arterial shear 
stress on the vascular wall and hence develops a tendency to 
atherosclerosis (104). Based on these data, it can be speculated 
that OPG is a protective mediator for atherosclerosis due to the 
inhibition of vascular calcification.
Atherosclerosis is also an immunological process. In an 
experimental study performed on unstable coronary plaques, 
increased expression levels of RANK-L from T cells and RANK 
from monocyte series were demonstrated by Shaker et al. (105). 
Therefore, it has been suggested that the increase in RANK-L 
is related to the increase in leukocyte response and matrix 
degradation, thus causing the inflammatory response. According 
to this conclusion, the interaction between RANK and RANK-L 
is attributed to plaque destabilization, and it can be speculated 
that as a decoy receptor for RANK-L, OPG behaves as an anti-
inflammatory mediator (105). There are various studies that 
proclaim the angiogenetic and favorable effects of the interaction 
between RANK and RANK-L on endothelial cell survival (106-
108). Seccihiero et al. (109) demonstrated that adding RANK-L 
into cell cultures, regardless of OPG presence, showed protective 
effects on endothelial cells by activating intracellular pathways, 
which results in nitric oxide synthesis. In another study, increased 
OPG levels were found in the presence of TNF-α, which can induce 
leukocyte adhesion molecule expression from endothelial cells and 
cause progression of atherogenesis (54).
OPG is a decoy receptor for TRAIL, which is attributed to 
TRAIL-associated apoptosis. TRAIL levels were found to 
have a negative correlation with CRP (110). Some researchers 
have concluded that by inhibiting TRAIL interaction with its 
receptor, OPG inhibits apoptosis and thereby intrudes the cellular 
barrier between the vessel lumen and plaque. In contrast, some 
researchers claim that OPG could increase leukocyte adhesion 
to endothelial cells both in vitro and in vivo with regard to 
the OPG’s heparin-binding region (54). Based on these data, 
it can be concluded that OPG behaves as a proinflammatory 
mediator for endothelial cells (54). Another explanation that 
indicates the proinflammatory behavior of OPG is by inhibiting 
TRAIL. Administration of TRAIL was shown to exhibit an anti-
atherosclerotic activity in apolipoprotein E-null diabetic mice 
(109). Therefore, as a decoy receptor for TRAIL, OPG might 
serve in favor of atherogenesis.
The conflicting results reported by different studies may be 
attributed to the different ELISA kits used for measuring OPG 
levels. OPG measurements can be done in both plasma and serum; 
therefore, caution is needed when comparing OPG levels from 
different studies due to the differences among sample types (111). 
OPG gene polymorphisms (112) may be another explanation for 
the divergent results in different studies.
No consensus is yet available on the function of OPG, but all 
these studies have concluded that OPG is a promising biomarker 
for CAD, regardless of whether it plays a protective role against 
atherosclerosis or causes atherosclerosis with its proatherogenic 
features. Further study is needed to define its role in pathogenesis 
and in the process of CVD.
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